25-NB explained

The 25-NB (25x-NBx) series, sometimes alternatively referred to as the NBOMe compounds, is a family of serotonergic psychedelics. They are substituted phenethylamines and were derived from the 2C family. They act as selective agonists of the serotonin 5-HT2A receptor.[1] [2] [3] [4] [5] [6] [7] The 25-NB family is unique relative to other classes of psychedelics in that they are, generally speaking, extremely potent and relatively selective for the 5-HT2A receptor. Use of NBOMe series drugs has caused many deaths and hospitalisations since the drugs popularisation in the 2010s. This is primarily due to their high potency, unpredictable pharmacokinetics, and sellers passing off the compounds in the series as LSD.[8]

Toxicity and harm potential

NBOMe compounds are often associated with life-threatening toxicity and death.[9] [10] Studies on NBOMe family of compounds demonstrated that the substance exhibit neurotoxic and cardiotoxic activity.[11] Reports of autonomic dysfunction remains prevalent with NBOMe compounds, with most individuals experiencing sympathomimetic toxicity such as vasoconstriction, hypertension and tachycardia in addition to hallucinations.[12] [13] [14] Other symptoms of toxidrome of include agitation or aggression, seizure, hyperthermia, diaphoresis, hypertonia, rhabdomyolysis, and death.[15] Researchers report that NBOMe intoxication frequently display signs of serotonin syndrome.[16] The likelihood of seizure is higher in NBOMes compared to other psychedelics.

NBOMe and NBOHs are regularly sold as LSD in blotter papers,[17] which have a bitter taste and different safety profiles. Despite high potency, recreational doses of LSD have only produced low incidents of acute toxicity. Fatalities involved in NBOMe intoxication suggest that a significant number of individuals ingested the substance which they believed was LSD,[18] and researchers report that "users familiar with LSD may have a false sense of security when ingesting NBOMe inadvertently". While most fatalities are due to the physical effects of the drug, there have also been reports of death due to self-harm and suicide under the influence of the substance.[19] [20]

Given limited documentation of NBOMe consumption, the long-term effects of the substance remain unknown. NBOMe compounds are not active orally, and are usually taken sublingually.[21] When NBOMes are administered sublingually, numbness of the tongue and mouth followed by a metallic chemical taste was observed, and researchers describe this physical side effect as one of the main discriminants between NBOMe compounds and LSD.[22] [23] [24]

Neurotoxic and cardiotoxic actions

Many of the NBOMe compounds have high potency agonist activity at additional 5-HT receptors and prolonged activation of 5-HT2B can cause cardiac valvulopathy in high doses and chronic use. 5-HT2B receptors have been strongly implicated in causing drug-induced valvular heart disease.[25] [26] [27] The high affinity of NBOMe compounds for adrenergic α1 receptor has been reported to contribute to the stimulant-type cardiovascular effects.

In vitro studies, 25C-NBOMe has been shown to exhibit cytotoxicity on neuronal cell lines SH-SY5Y, PC12, and SN471, and the compound was more potent than methamphetamine at reducing the visibility of the respective cells; the neurotoxicity of the compound involves activation of MAPK/ERK cascade and inhibition of Akt/PKB signaling pathway. 25C-NBOMe, including the other derivative 25D-NBOMe, reduced the visibility of cardiomyocytes H9c2 cells, and both substances downregulated expression level of p21 (CDC24/RAC)-activated kinase 1 (PAK1), an enzyme with documented cardiac protective effects.

Preliminary studies on 25C-NBOMe have shown that the substance is toxic to development, heart health, and brain health in zebrafish, rats, and Artemia salina, a common organism for studying potential drug effects on humans, but more research is needed on the topic, the dosages, and if the toxicology results apply to humans. Researchers of the study also recommended further investigation of the drug's potential in damaging pregnant women and their fetus due to the substance's damaging effects to development.[28] [29]

Emergency treatment

At present, there are no specific antidotes for NBOMes, and all acute intoxication is managed by symptomatic treatments, such as administration of benzodiazepines, antipsychotic drugs, and antiarrhythmic agents, such as beta blockers; some emergency interventions are intended to specifically treat rhabdomyolysis, which may lead to critical complications such as metabolic acidosis and acute kidney injury.

Chemical structure

The 25-NB compounds are mostly N-benzylphenethylamines,[30] though in some cases the phenyl ring of the N-benzyl group is replaced by other heterocycles such as thiophene, pyridine, furan, tetrahydrofuran, benzodioxole or naphthalene, among others.[31] [32]

Generally speaking, they have methoxy groups at the 2 and 5 positions of the phenyl ring, a substitution such as a halogen or alkyl group at the 4 position of the phenyl ring, and a methoxy or other substitution (e.g., hydroxyl, fluoro) at the 2 position of the N-benzyl ring. More rarely, other substitution patterns may be present [33] [34] (see e.g. NBOMe-mescaline, 25G-NBOMe, 2CBFly-NBOMe, 25C-NB3OMe). They differ from the 2C series by the presence of the N-benzyl moiety.

Rarely an alpha-methyl group is present making them N-benzyl amphetamines rather than N-benzyl phenethylamines, but this greatly reduces potency and activity. However in some cases where a side chain methyl group is cyclised back to the ring (e.g. in 2CBCB-NBOMe) or links the two alpha positions (e.g. in DMBMPP), this can improve selectivity for the 5-HT2A receptor subtype.[35]

List of 25-NB derivatives

This list includes notable compounds representative of most of the structural variations that have been explored in this series, but is by no means exhaustive. Many derivatives invented for scientific study into the structure-activity relationships of 5-HT2 receptor agonists have never appeared as designer drugs, while conversely some derivatives that have appeared as designer drugs are structurally novel and of unknown pharmacological activity (e.g. C30-NBOMe, 5-APB-NBOMe).

Chemical structureCommon nameChemical nameCAS numberRR1Cyc
25B-NBN-benzyl-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane155639-26-22,5-dimethoxy-4-bromoHphenyl
25C-NBN-benzyl-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane1391487-65-22,5-dimethoxy-4-chloroHphenyl
25I-NBN-benzyl-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane919797-18-52,5-dimethoxy-4-iodoHphenyl
25I-NMeThN-[(thiophen-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane1391499-03-82,5-dimethoxy-4-iodoHthiophen-2-yl
25B-NMePyrN-[(pyridin-2-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1391499-21-02,5-dimethoxy-4-bromoHpyridin-2-yl
25I-NMeFurN-[(furan-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane1391498-93-32,5-dimethoxy-4-iodoHfuran-2-yl
25I-NMeTHFN-[(tetrahydrofuran-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane2,5-dimethoxy-4-iodoHtetrahydrofuran-2-yl
25B-NBFN-(2-fluorobenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1539266-17-52,5-dimethoxy-4-bromoH2-fluorophenyl
25B-NBOHN-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1335331-46-82,5-dimethoxy-4-bromoH2-hydroxyphenyl
25B-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1026511-90-92,5-dimethoxy-4-bromoH2-methoxyphenyl
25B-NB23DMN-(2,3-dimethoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1391493-68-72,5-dimethoxy-4-bromoH2,3-dimethoxyphenyl
25B-NB25DMN-(2,5-dimethoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane2,5-dimethoxy-4-bromoH2,5-dimethoxyphenyl
25B-NMe7BFN-[(benzofuran-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1391492-46-82,5-dimethoxy-4-bromoHbenzofuran-7-yl
25B-NMe7DHBFN-[(2,3-dihydrobenzofuran-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1391492-40-22,5-dimethoxy-4-bromoH2,3-dihydrobenzofuran-7-yl
25B-NMe7BTN-[(benzothiophen-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1391492-59-32,5-dimethoxy-4-bromoHbenzothiophen-7-yl
25B-NMe7BoxN-[(benzoxazol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1391498-73-92,5-dimethoxy-4-bromoHbenzoxazol-7-yl
25B-NMe7IndN-[(indol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1391498-28-42,5-dimethoxy-4-bromoHindol-7-yl
25B-NMe7IndzN-[(indazol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1391498-43-32,5-dimethoxy-4-bromoHindazol-7-yl
25B-NMe7BimN-[(benzimidazol-7-yl)methyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1391498-62-62,5-dimethoxy-4-bromoHbenzimidazol-7-yl
FECIMBI-36N-[(2-fluoroethoxy)benzyl]-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane2,5-dimethoxy-4-bromoH2-(2-fluoroethoxy)phenyl
DOB-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane2,5-dimethoxy-4-bromomethyl2-methoxyphenyl
25C-NB3OMeN-(3-methoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane1566571-34-32,5-dimethoxy-4-chloroH3-methoxyphenyl
25C-NB4OMeN-(4-methoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane1566571-35-42,5-dimethoxy-4-chloroH4-methoxyphenyl
C30-NBOMeN-(3,4,5-trimethoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane1445574-98-02,5-dimethoxy-4-chloroH3,4,5-trimethoxyphenyl
25C-NBFN-(2-fluorobenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane1539266-21-12,5-dimethoxy-4-chloroH2-fluorophenyl
25C-NBClN-(2-chlorobenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane2,5-dimethoxy-4-chloroH2-chlorophenyl
25C-NBOHN-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane1391488-16-62,5-dimethoxy-4-chloroH2-hydroxyphenyl
25C-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane1227608-02-72,5-dimethoxy-4-chloroH2-methoxyphenyl
25C-NBOEtN-(2-ethoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane2,5-dimethoxy-4-chloroH2-ethoxyphenyl
25C-NBOiPrN-(2-isopropoxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane2,5-dimethoxy-4-chloroH2-isopropoxyphenyl
25F-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-fluorophenyl)-2-aminoethane1373917-84-02,5-dimethoxy-4-fluoroH2-methoxyphenyl
25CN-NBOHN-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-cyanophenyl)-2-aminoethane1539266-32-42,5-dimethoxy-4-cyanoH2-hydroxyphenyl
25CN-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-cyanophenyl)-2-aminoethane1354632-16-82,5-dimethoxy-4-cyanoH2-methoxyphenyl
25D-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-methylphenyl)-2-aminoethane1354632-02-22,5-dimethoxy-4-methylH2-methoxyphenyl
25D-NBOHN-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-methylphenyl)-2-aminoethane1391488-44-02,5-dimethoxy-4-methylH2-hydroxyphenyl
25E-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-ethylphenyl)-2-aminoethane1354632-14-62,5-dimethoxy-4-ethylH2-methoxyphenyl
25E-NBOHN-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-ethylphenyl)-2-aminoethane1391489-79-42,5-dimethoxy-4-ethylH2-hydroxyphenyl
25G-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-3,4-dimethylphenyl)-2-aminoethane1354632-65-72,5-dimethoxy-3,4-dimethylH2-methoxyphenyl
25H-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxyphenyl)-2-aminoethane1566571-52-52,5-dimethoxyH2-methoxyphenyl
25I-NB34MDN-(3,4-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane1391497-81-62,5-dimethoxy-4-iodoH3,4-methylenedioxyphenyl
25I-NB3OMeN-(3-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane 1566571-40-12,5-dimethoxy-4-iodoH3-methoxyphenyl
25I-NB4OMeN-(4-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane1566571-41-22,5-dimethoxy-4-iodoH4-methoxyphenyl
25I-NBFN-(2-fluorobenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane919797-21-02,5-dimethoxy-4-iodoH2-fluorophenyl
25I-NBBrN-(2-bromobenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane1648649-98-22,5-dimethoxy-4-iodoH2-bromophenyl
25I-NBTFMN-[2-(trifluoromethyl)benzyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane2,5-dimethoxy-4-iodoH2-(trifluoromethyl)phenyl
25I-NBMDN-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane919797-25-42,5-dimethoxy-4-iodoH2,3-methylenedioxyphenyl
25B-NBMDN-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminoethane1354632-19-12,5-dimethoxy-4-bromoH2,3-methylenedioxyphenyl
25C-NBMDN-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-chlorophenyl)-2-aminoethane1373879-26-52,5-dimethoxy-4-chloroH2,3-methylenedioxyphenyl
25D-NBMDN-(2,3-methylenedioxybenzyl)-1-(2,5-dimethoxy-4-methylphenyl)-2-aminoethane1391488-97-32,5-dimethoxy-4-methylH2,3-methylenedioxyphenyl
25I-NBOHN-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane919797-20-92,5-dimethoxy-4-iodoH2-hydroxyphenyl
25I-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane919797-19-62,5-dimethoxy-4-iodoH2-methoxyphenyl
DOI-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane2,5-dimethoxy-4-iodomethyl2-methoxyphenyl
25I-NBMeOHN-[2-(hydroxymethyl)benzyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane1391494-71-52,5-dimethoxy-4-iodoH2-(hydroxymethyl)phenyl
25I-NBAmN-[2-(carbamoyl)benzyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane1391494-85-12,5-dimethoxy-4-iodoH2-(carbamoyl)phenyl
25I-NMe7DHBFN-[(2,3-dihydrobenzofuran-7-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane2,5-dimethoxy-4-iodoH2,3-dihydrobenzofuran-7-yl
25I-N2Nap1OHN-[(1-hydroxynaphthalen-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane2,5-dimethoxy-4-iodoH1-hydroxynaphthalen-2-yl
25I-N3MT2MN-[(3-methoxythiophen-2-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane1354632-66-82,5-dimethoxy-4-iodoH3-methoxythiophen-2-yl
25I-N4MT3MN-[(4-methoxythiophen-3-yl)methyl]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane1354632-73-72,5-dimethoxy-4-iodoH4-methoxythiophen-3-yl
25iP-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-isopropylphenyl)-2-aminoethane1391487-83-42,5-dimethoxy-4-isopropylH2-methoxyphenyl
25N-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane1354632-03-32,5-dimethoxy-4-nitroH2-methoxyphenyl
25N-NBOEt [36] N-(2-ethoxybenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane2,5-dimethoxy-4-nitroH2-ethoxyphenyl
25N-NB-2-OH-3-MeN-(2-hydroxy-3-methylbenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane2,5-dimethoxy-4-nitroH2-hydroxy-3-methylphenyl
25N-NBOCF2HN-(2-difluoromethoxybenzyl)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane2,5-dimethoxy-4-nitroH2-difluoromethoxyphenyl
25N-NBPh[37] N-[(2-phenyl)benzyl]-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane2,5-dimethoxy-4-nitroHo-biphenyl
25N-N1-NapN-[(naphthalen-1-yl)methyl]-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminoethane2,5-dimethoxy-4-nitroH1-naphthyl
25P-NBOMeN-(2-methoxybenzyl)-1-(2,5-dimethoxy-4-propylphenyl)-2-aminoethane1391489-07-82,5-dimethoxy-4-propylH2-methoxyphenyl
25P-NBOHN-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-propylphenyl)-2-aminoethane1391490-34-82,5-dimethoxy-4-propylH2-hydroxyphenyl
25TFM-NBOMeN-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(trifluoromethyl)phenyl]-2-aminoethane1027161-33-62,5-dimethoxy-4-(trifluoromethyl)H2-methoxyphenyl
25O-NBcPN-(2-cyclopropylbenzyl)-1-(2,4,5-trimethoxyphenyl)-2-aminoethane2,4,5-trimethoxyH2-cyclopropylphenyl
25T-NBOMeN-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(methylthio)phenyl]-2-aminoethane1539266-47-12,5-dimethoxy-4-(methylthio)H2-methoxyphenyl
25T2-NBOMeN-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(ethylthio)phenyl]-2-aminoethane1539266-51-72,5-dimethoxy-4-(ethylthio)H2-methoxyphenyl
25T4-NBOMeN-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(isopropylthio)phenyl]-2-aminoethane1354632-17-92,5-dimethoxy-4-(isopropylthio)H2-methoxyphenyl
25T7-NBOMeN-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-(propylthio)phenyl]-2-aminoethane1539266-55-12,5-dimethoxy-4-(propylthio)H2-methoxyphenyl
25T7-NBOHN-(2-hydroxybenzyl)-1-[2,5-dimethoxy-4-(propylthio)phenyl]-2-aminoethane1354632-41-92,5-dimethoxy-4-(propylthio)H2-hydroxyphenyl
25AM-NBOMe [38] N-(2-methoxybenzyl)-1-[2,5-dimethoxy-4-pentylphenyl]-2-aminoethane2,5-dimethoxy-4-(n-pentyl)H2-methoxyphenyl
NBOMe-mescalineN-(2-methoxybenzyl)-1-(3,4,5-trimethoxyphenyl)-2-aminoethane1354632-01-13,4,5-trimethoxyH2-methoxyphenyl
NBOMe-escalineN-(2-methoxybenzyl)-1-(3,5-dimethoxy-4-ethoxyphenyl)-2-aminoethane3,5-dimethoxy-4-ethoxyH2-methoxyphenyl
NBOMe-thiobuscalineN-(2-methoxybenzyl)-1-(3,5-dimethoxy-4-butylthiophenyl)-2-aminoethane3,5-dimethoxy-4-(n-butylthio)H2-methoxyphenyl
MDPEA-NBOMeN-(2-methoxybenzyl)-1-(3,4-methylenedioxyphenyl)-2-aminoethane3,4-methylenedioxyH2-methoxyphenyl
2C2-NBOMeN-(2-methoxybenzyl)-1-(2-methoxy-4,5-methylenedioxyphenyl)-2-aminoethane2-methoxy-4,5-methylenedioxyH2-methoxyphenyl
MDBZN-benzyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane65033-29-63,4-methylenedioxymethylphenyl
ClobenzorexN-(2-chlorobenzyl)-1-phenyl-2-aminopropane13364-32-4Hmethyl2-chlorophenyl
4-EA-NBOMeN-(2-methoxybenzyl)-1-(4-ethylphenyl)-2-aminopropane4-ethylmethyl2-methoxyphenyl
5-APB-NBOMeN-(2-methoxybenzyl)-1-(benzofuran-5-yl)-2-aminopropanebenzofuran-5-yl instead of phenylmethyl2-methoxyphenyl

Related compounds

Similar compounds with related structures are also known including;

Chemical structureCommon nameChemical nameCAS number
25B-N1POMeN-[1-(2-methoxyphenyl)ethyl]-2,5-dimethoxy-4-bromophenethylamine1335331-49-1 (R)
1335331-51-5 (S)
2C-B-AN [39] [40] 2-phenyl-2-[2-(2,5-dimethoxy-4-bromophenyl)ethylamino]acetonitrile
25B-N(BOMe)22-(4-Bromo-2,5-dimethoxyphenyl)-N,N-bis(2-methoxybenzyl)ethan-1-amine
25CN-N3DHBF[41] 4-(2-[(2,3-dihydro-1-benzofuran-3-yl)amino]ethyl)-2,5-dimethoxybenzonitrile
2CBCB-NBOMeN-[(3-bromo-2,5-dimethoxy-bicyclo[4,2,0]octa-1,3,5-trien-7-yl)methyl]-1-(2-methoxyphenyl)methanamine1354634-09-5
2CBFly-NBOMeN-(2-methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane1335331-42-4
2C-B-DRAGONFLY-NBOHN-(2-hydroxybenzyl)-1-(8-bromobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane1335331-45-7
2C-B-FLY-NB2EtO5Cl [42] N-(2-ethoxy-5-chlorobenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane
DMBMPP(S,S)-2-(2,5-dimethoxy-4-bromobenzyl)-6-(2-methoxyphenyl)piperidine1391499-52-7
25B-NAcPip2--1-(piperidin-1-yl)ethanone
ZDCM-041,3-dimethyl-7-purine-2,6-dione
RH-343-[2-(2-methoxybenzylamino)ethyl]-1H-quinazoline-2,4-dione1028307-48-3
5-MeO-T-NBOMe[43] N-(2-methoxybenzyl)-5-methoxytryptamine1335331-37-7
5MT-NB3OMeN-(3-methoxybenzyl)-5-methoxytryptamine1648553-42-7

Legality

United Kingdom

A large number of substances in the 25-NB class are Class A drugs in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971[44] or are otherwise covered by the Psychoactive Substances Act 2016.[45]

See also

External links

Notes and References

  1. N-Benzylated derivatives of the hallucinogenic drugs mescaline and escaline as partial agonists at rat vascular 5-HT2A receptors . https://web.archive.org/web/20150925085048/http://bitnest.ca/external.php?id=%2502%257F%2505J%2516%251A%2509%2504%2504e%255C%25258%2522UV%2508%2507N%2501Q%2540i%251Ec%250B7kq . dead . September 25, 2015 . Naunyn-Schmiedeberg's Archives of Pharmacology . 1999-01-01 . 359 . . R29 . Pertz HH, Rheineck A, Elz S .
  2. Heim R . Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. . Berlin . Freie Univ. . February 28, 2010 . de . 2013-05-10.
  3. Silva M . Theoretical study of the interaction of agonists with the 5-HT2A receptor . Ph.D. . Universität Regensburg . 2009 .
  4. Ph.D. . Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain. . Hansen M . University of Copenhagen . 2011 .
  5. Silva ME, Heim R, Strasser A, Elz S, Dove S . Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor . Journal of Computer-Aided Molecular Design . 25 . 1 . 51–66 . January 2011 . 21088982 . 10.1007/s10822-010-9400-2 . 3103050 . 10.1.1.688.2670 . 2011JCAMD..25...51S .
  6. Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME . Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs) . Neuropharmacology . 99 . 546–553 . December 2015 . 26318099 . 10.1016/j.neuropharm.2015.08.034 . 10382311 .
  7. Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, Kristensen JL . Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists . ACS Chemical Neuroscience . 5 . 3 . 243–249 . March 2014 . 24397362 . 3963123 . 10.1021/cn400216u .
  8. Lipow M, Kaleem SZ, Espiridion E . 2022-03-30 . NBOMe Toxicity and Fatalities: A Review of the Literature . Transformative Medicine . 1 . 1 . 12–18 . 10.54299/tmed/msot8578 . 247888583 . 2831-8978. free .
  9. . A cluster of 25B-NBOH poisonings following exposure to powder sold as lysergic acid diethylamide (LSD) . 10.1080/15563650.2022.2053150 . Sean I, Joe R, Jennifer S, and Shaun G . 966–969 . 28 March 2022 . 60 . 8 . 35343858. 247764056 .
  10. Biochemical Pharmacology . Amy E, Katherine W, John R, Sonyoung K, Robert J, Aaron J . Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors . 10.1016/j.bcp.2018.09.024 . 30261175 . 6298744 . 158 . 27–34 . December 2018.
  11. Frontiers in Neuroscience . Jolanta Z, Monika K, and Piotr A . 10.3389/fnins.2020.00078 . 26 February 2020 . 14 . 32174803 . NBOMes–Highly Potent and Toxic Alternatives of LSD . 78 . 7054380 . free .
  12. Front Psychiatry . Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs . Micaela T, Sabrine B, Raffaella A, Giorgia C, Beatrice M, Tatiana B, Federica B, Giovanni S, Francesco B, Fabio G, Krystyna G, Matteo M . 35530025 . 9069068 . 10.3389/fpsyt.2022.875722 . 21 April 2022 . 13 . 875722 . free .
  13. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs) . Neuropharmacology . 10.1016/j.neuropharm.2015.08.034 . 26318099 . Anna R, Dino L, Julia R, Daniele B, Marius H, Matthias L . 546–553 . December 2015 . 99 . 10382311 . 1873-7064.
  14. Clinical Toxicology . Prevalence of use and acute toxicity associated with the use of NBOMe drugs . David W, Roumen S, Andrew C, Paul D . 10.3109/15563650.2015.1004179 . 6 February 2015 . 85–92 . 53 . 2 . 25658166. 25752763 .
  15. Lipow M, Kaleem SZ, Espiridion E . 30 March 2022 . NBOMe Toxicity and Fatalities: A Review of the Literature . Transformative Medicine . 1 . 1 . 12–18 . 10.54299/tmed/msot8578 . 247888583 . 2831-8978 . free .
  16. Humston C, Miketic R, Moon K, Ma P, Tobias J . 2017-06-05 . Toxic Leukoencephalopathy in a Teenager Caused by the Recreational Ingestion of 25I-NBOMe: A Case Report and Review of Literature . Journal of Medical Cases . 8 . 6 . 174–179 . 10.14740/jmc2811w . 1923-4163. free .
  17. Journal of Analytical Toxicology . 10.1093/jat/bkv073 . 4570937 . 26378135 . Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper . Justin P, Stephen R, Kylin A, Alphonse P, Michelle P . 2015 . 39 . 8 . 617–623.
  18. Frontiers in Pharmacology . 12 December 2019 . 10.3389/fphar.2019.01406 . Cristina M, Matteo M, Nicholas P, Maria C, Micaela T, Raffaella A, Maria L . Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe . 10 . 1406 . 31915427 . 6921684 . free .
  19. Morini L, Bernini M, Vezzoli S, Restori M, Moretti M, Crenna S, Papa P, Locatelli C, Osculati AM, Vignali C, Groppi A . 6 . Death after 25C-NBOMe and 25H-NBOMe consumption . Forensic Science International . 279 . e1–e6 . October 2017 . 28893436 . 10.1016/j.forsciint.2017.08.028 .
  20. Byard RW, Cox M, Stockham P . Blunt Craniofacial Trauma as a Manifestation of Excited Delirium Caused by New Psychoactive Substances . Journal of Forensic Sciences . 61 . 6 . 1546–1548 . November 2016 . 27723094 . 10.1111/1556-4029.13212 . 4734566 .
  21. Book: Neuropharmacology of New Psychoactive Substances . Adam H . 10.1007/7854_2016_64 . 18 January 2017 . 978-3-319-52444-3 . Springer . https://link.springer.com/chapter/10.1007/7854_2016_64 . Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens . Current Topics in Behavioral Neurosciences . 32 . 283–311 . 28097528.
  22. Boris D, Cristian C, Marcelo K, Edwar F, Bruce KC . Journal of Chromatographic Science . 54 . 7 . August 2016 . 1153–1158 . Analysis of 25 C NBOMe in Seized Blotters by HPTLC and GC–MS . 4941995 . 27406128 . 10.1093/chromsci/bmw095 .
  23. 25105138 . 4106087 . 10.1155/2014/734749 . 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug . BioMed Research International . 3 July 2014 . Francesco SB, Ornella C, Gabriella A, Giuseppe V, Rita S, Flaminia BP, Eduardo C, Pierluigi S, Giovanni M, Guiseppe B, Fabrizio S . 2014 . 734749 . free .
  24. Book: Novel Psychoactive Substances: Classification, Pharmacology and Toxicology . Pharmacology and toxicology of N-Benzyl-phenylethylamines (25X-NBOMe) hallucinogens . Adam JP, Simon HT, Simon LH . 10.1016/B978-0-12-818788-3.00008-5 . 978-0-12-818788-3 . 279–300 . 2 . Academic Press . September 2021 . 240583877 . https://www.sciencedirect.com/science/article/abs/pii/B9780128187883000085.
  25. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Bryan Roth . Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications . Circulation . 102 . 23 . 2836–41 . Dec 2000 . 11104741 . 10.1161/01.CIR.102.23.2836 . free .
  26. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW . Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine . Molecular Pharmacology . 57 . 1 . 75–81 . Jan 2000 . 10617681 .
  27. Roth BL . Drugs and valvular heart disease . The New England Journal of Medicine . 356 . 1 . 6–9 . Jan 2007 . 17202450 . 10.1056/NEJMp068265 .
  28. Xu P, Qiu Q, Li H, Yan S, Yang M, Naman CB, Wang Y, Zhou W, Shen H, Cui W . 6 . 25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro . Neurotoxicity Research . 35 . 4 . 993–998 . 26 February 2019 . 30806983 . 10.1007/s12640-019-0012-x . 255763701.
  29. Álvarez-Alarcón N, Osorio-Méndez JJ, Ayala-Fajardo A, Garzón-Méndez WF, Garavito-Aguilar ZV . Zebrafish and Artemia salina in vivo evaluation of the recreational 25C-NBOMe drug demonstrates its high toxicity . Toxicology Reports . 8 . 315–323 . 2021 . 2214-7500 . 33598409 . 7868744 . 10.1016/j.toxrep.2021.01.010 .
  30. Poulie CB, Jensen AA, Halberstadt AL, Kristensen JL . DARK Classics in Chemical Neuroscience: NBOMes . ACS Chemical Neuroscience . 11 . 23 . 3860–3869 . December 2020 . 31657895 . 9191638 . 10.1021/acschemneuro.9b00528 . 204952449 .
  31. Towards a biophysical understanding of hallucinogen action . 1–176 . Dissertation . 2007 . Michael Robert Braden.
  32. 10.1002/wmts.42. Structure-activity relationships of serotonin 5-HT2A agonists. 2012. Nichols DE . Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 1. 5. 559–579. free.
  33. Leth-Petersen S, Petersen IN, Jensen AA, Bundgaard C, Bæk M, Kehler J, Kristensen JL . 5-HT2A/5-HT2C Receptor Pharmacology and Intrinsic Clearance of N-Benzylphenethylamines Modified at the Primary Site of Metabolism . ACS Chemical Neuroscience . 7 . 11 . 1614–1619 . November 2016 . 27564969 . 10.1021/acschemneuro.6b00265 .
  34. Prabhakaran J, Solingapuram Sai KK, Zanderigo F, Rubin-Falcone H, Jorgensen MJ, Kaplan JR, Tooke KI, Mintz A, Mann JJ, Kumar JS . 6 . In vivo evaluation of [<sup>18</sup>F]FECIMBI-36, an agonist 5-HT2A/2C receptor PET radioligand in nonhuman primate . Bioorganic & Medicinal Chemistry Letters . 27 . 1 . 21–23 . January 2017 . 27889455 . 5348621 . 10.1016/j.bmcl.2016.11.043 .
  35. Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE . Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands . ACS Chemical Neuroscience . 4 . 1 . 96–109 . January 2013 . 23336049 . 3547484 . 10.1021/cn3000668 .
  36. https://patentscope.wipo.int/search/docs2/pct/WO2022241006/pdf/lmn6TeZvVxwrWfMPGXSgGF69Nq0S8wI_Iu8YPRg1oG0fVxgZawU-hohjRNXGqyF-mWFzDNdhngqdzZcOiaG51t8ktcDQhlNixeva5waz3NGeeRkYShI9sEy_F6uKFygr?docId=id00000069605752&filename=WO2022241006-PAMPH-20221117-5752.pdf Wallach J, et al. Selective, Partial and Arrestin-Biased 5-HT2A Agonists with Utility in Various Disorders. Patent WO 2022/241006
  37. Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD. Identification of 5-HT2A Receptor Signaling Pathways Responsible for Psychedelic Potential. bioRxiv 2023 Jul 31:2023.07.29.551106.
  38. https://patentscope.wipo.int/search/docs2/pct/WO2022192781/pdf/QOzjQmIyWwrEclmUct9kaFMeAK70TxX-ImugW-teD6g1MJV7mZsw5f0qws6CCgdqi1cb0qYJk8gHQ7um-dl4IOUKpg2KpVS3y24AFsG7xyWyzHruOlmpyBP_mK154b3F?docId=id00000068397619&filename=WO2022192781-PAMPH-20220915-7619.pdf Kruegel AC. Phenalkylamines and Methods of Making and Using the Same. Patent WO 2022/192781
  39. Book: Trachsel D, Lehmann D, Enzensperger C . Phenethylamine Von der Struktur zur Funktion . 843 . Nachtschatten Verlag AG . 2013 . 978-3-03788-700-4.
  40. Elliott SP, Holdbrook T, Brandt SD . Prodrugs of New Psychoactive Substances (NPS): A New Challenge . Journal of Forensic Sciences . 65 . 3 . 913–920 . May 2020 . 31943218 . 10.1111/1556-4029.14268 . 210335207 .
  41. Bolinger AA, et al. The Serotonin 5-HT2A Receptor as an Evolving Neurotherapeutic Target. Medicinal Chemistry Reviews 2023; 58(3): 53-81.
  42. 10.1007/s11419-019-00498-7. In vitro toxicokinetics and analytical toxicology of three novel NBOMe derivatives: Phase I and II metabolism, plasma protein binding, and detectability in standard urine screening approaches studied by means of hyphenated mass spectrometry. 2020. Richter LH, Menges J, Wagmann L, Brandt SD, Stratford A, Westphal F, Flockerzi V, Meyer MR . 6 . Forensic Toxicology. 38. 141–159. 202879918.
  43. Nichols DE, Sassano MF, Halberstadt AL, Klein LM, Brandt SD, Elliott SP, Fiedler WJ . N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues . ACS Chemical Neuroscience . 6 . 7 . 1165–1175 . July 2015 . 25547199 . 4505863 . 10.1021/cn500292d .
  44. Web site: The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014. www.legislation.gov.uk. en.
  45. Web site: Psychoactive Substances Act 2016. www.legislation.gov.uk. en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "25-NB".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.